Select the drug indication to add to your list


Bacterial infections
Only 4 drugs may be compared at once

Generic Name and Formulations:

Daptomycin 500mg/vial; lyophilized pwd for IV inj after reconstitution (with 0.9% sodium chloride) or IV infusion after reconstitution and dilution; preservative-free; requires refrigeration.

Select therapeutic use:

Indications for CUBICIN:

Susceptible complicated skin and skin structure infections (cSSSI) in adults and pediatrics (1–17yrs). S. aureus bacteremia including MRSA and MSSA right-sided endocarditis in adults.

Limitations Of use:

Not for treatment of pneumonia or left-sided endocarditis due to S. aureus. Not studied in prosthetic valve endocarditis. Not recommended in pediatrics (<1yr) due to risk of potential effects on muscular, neuromuscular, and/or nervous systems (peripheral and/or central).


Give by IV inj over 2 mins or IV infusion over 30mins. cSSSI: 4mg/kg once every 24hrs for 7–14 days. S. aureus bacteremia or endocarditis: 6mg/kg once every 24hrs for 2–6 weeks. Renal impairment (CrCl <30mL/min): decrease dosing interval to once every 48hrs; coincide dose for after dialysis.


S. aureus bacteremia: <18yrs: not established. cSSSI: <1yr: not established. Give by IV infusion up to 14 days. 1–<2yrs: 10mg/kg once every 24hrs over 60mins; 2–6yrs: 9mg/kg once every 24hrs over 60mins; 7–11yrs: 7mg/kg once every 24hrs over 30mins; 12–17yrs: 5mg/kg once every 24hrs over 30mins.


Monitor for development of muscle pain or weakness (esp. distal extremities). Monitor CPK weekly (more frequently in those with concomitant statin therapy or elevated CPK); discontinue if CPK (≥5xULN) and myopathy occur, or if CPK (≥10xULN) without myopathy occurs. Renal impairment: monitor renal function and CPK more frequently than once weekly. Discontinue immediately if eosinophilic pneumonia develops; treat with systemic steroids. Monitor for neuropathy; consider discontinuation if occurs. Persisting or relapsing S. aureus bacteremia/endocarditis: repeat blood cultures and evaluate. Decreased efficacy observed in adults with moderate baseline renal impairment. Severe hepatic impairment. Pregnancy. Nursing mothers.


Consider suspending agents associated with rhabdomyolysis (eg, statins). May cause false prolongation of PT or elevation of INR when certain recombinant thromboplastin reagents are utilized for the assay.

See Also:


Pharmacological Class:

Cyclic lipopeptide.

Adverse Reactions:

Diarrhea, headache, dizziness, rash, abnormal LFTs, elevated CPK, UTIs, hypotension, dyspnea, vomiting, abdominal pain, pruritus, pyrexia, sepsis, bacteremia, chest pain, edema, pharyngolarygeal pain, increased sweating, insomnia, hypertension; hypersensitivity reactions, myopathy, rhabdomyolysis, C. difficile-associated diarrhea.

How Supplied:

Single-dose vial (10mL)—1

CUBICIN 500mg vials (Qty:1)

appx. price $476.00